Evidence map›Paper›PMID 40034593›Full record

ArticleFrontiers in oncology2025

Machine learning models for predicting prostate cancer recurrence and identifying potential molecular biomarkers.

Maria Eliza Antunes, Thaise Gonçalves Araújo, Tatiana Martins Till, Eliana Pantaleão, Paulo F A Mancera, Marta Helena de Oliveira

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maria Eliza AntunesGraduate Program in Biometrics, Instituto de Biociências de Botucatu (IBB), Universidade Estadual Paulista (UNESP), Botucatu, São Paulo, Brazil.
Thaise Gonçalves AraújoInstitute of Biotechnology, Universidade Federal de Uberlândia (UFU), Patos de Minas, Minas Gerais, Brazil.
Tatiana Martins TillLaboratory of Clinical and Experimental Pathophysiology, Instituto Oswaldo Cruz (IOC), Rio de Janeiro, Rio de Janeiro, Brazil.
Eliana PantaleãoSchool of Computing, Universidade Federal de Uberlândia (UFU), Patos de Minas, Minas Gerais, Brazil.
Paulo F A ManceraDepartment of Biodiversity and Biostatistics, Instituto de Biociências de Botucatu (IBB), Universidade Estadual Paulista (UNESP), Botucatu, São Paulo, Brazil.
Marta Helena de OliveiraInstitute of Mathematics and Statistics, Universidade Federal de Uberlândia (UFU), Patos de Minas, Minas Gerais, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) recurrence affects between 20% and 40% of patients, being a significant challenge for predicting clinical outcomes and increasing survival rates. Although serum PSA levels, Gleason score, and tumor staging are sensitive for detecting recurrence, they present low specificity. This study compared the performance of three supervised machine learning models, Naive Bayes (NB), Support Vector Machine (SVM), and Artificial Neural Network (ANN) for classifying PCa recurrence events using a dataset of 489 patients from The Cancer Genome Atlas (TCGA). Besides comparing the models performance, we searched for analyzing whether the incorporation of specific genes expression in the predictor set would enhance the prediction of PCa recurrence, then suggesting these genes as potential biomarkers of patient prognosis. The models showed accuracy above 60% and sensitivity above 65% in all combinations. ANN models were more consistent in their performance across different predictor sets. Notably, SVM models showed strong results in precision and specificity, particularly considering the inclusion of genes selected by feature selection (

Indexed as

artificial intelligencemolecular markersnext generation sequencingprognosticsupervised learning

Identifiers

PMID40034593
PMCPMC11873604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.